<DOC>
	<DOCNO>NCT01449162</DOCNO>
	<brief_summary>The study objective compare efficacy safety masitinib 6 mg/kg/day versus placebo treatment patient Severe Persistent Asthma treat oral corticosteroid .</brief_summary>
	<brief_title>A Phase 3 Study Compare Efficacy Safety Masitinib Placebo Treatment Patients With Severe Persistent Asthma Treated With Oral Corticosteroids</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>1 . Patient severe persistent asthma already treat 2 . Patient history asthma &gt; 1 year prior screen visit 3 . Patient significant change regular asthma medication , severe asthma exacerbation least 4 week prior screen visit 4 . Nonsmoker patient least one year prior tobacco consumption &lt; 10 pack year 1 . Asthmatic patient still expose allergen trigger factor influence asthma control 2 . Patient history acute infectious sinusitis respiratory tract infection within 4 week prior screen 3 . Patient present cardiac disorder 4 . Patient active lung disease asthma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>severe persistent asthma</keyword>
	<keyword>patient treat oral corticosteroid</keyword>
</DOC>